MISSISSAUGA, ON, Aug. 8, 2024
/CNW/ -- Abbott (NYSE: ABT) today announced that the Government of
Quebec's Régie de l'assurance
maladie du Québec (RAMQ) published an update to its formulary that
includes expanded reimbursement for Abbott's FreeStyle Libre
2* flash glucose monitoring system to more adults living
with type 1 and type 2 diabetes.
As of July 4, 2024, provincial
reimbursement criteria expanded for individuals 18 years of age and
older with type 1 or type 2 diabetes who are treated with intensive
insulin to include those who also meet one or more of the following
criteria: Those who have not been able to achieve their targeted
hemoglobin A1c (HbA1c) or who are unable to recognize or
report symptoms of hypoglycemia.
Previously, coverage was only available for individuals 18 years
of age and older who were treated with intensive insulin and
had frequent episodes of hypoglycemia, or for residents under the
age of 18 who have type 1 diabetes. (Coverage remains the same for
these individuals.)
Quebec was one of the first
Canadian provinces to reimburse flash glucose monitoring technology
in 2019. The FreeStyle Libre 2 is the only sensor-based technology
available for those living with type 2 diabetes in Quebec who meet RAMQ's criteria.
"This is great news for the residents of Quebec who are living with diabetes and who
previously were not able to access a flash glucose monitoring
system," said Dr. Claude Garceau
internist at the Institut universitaire de cardiologie et de
pneumologie de Québec – Université Laval. "Providing expanded access to the
FreeStyle Libre 2 system helps more people manage their diabetes
with life-changing technology that eases the burden of everyday
care."
Abbott's FreeStyle Libre 2 system represents a significant
advancement in diabetes management. The system continues to be the
market leader in Quebec and the
world's leading sensor-based glucose monitoring system1.
It is the most affordable2 technology and the only
system that delivers 14 days of automatic glucose readings sent
every minute3 directly to one's
smartphone§.
"As advocates for people living with diabetes in Quebec, improving and expanding access to
critical tools, like flash glucose monitoring, to help them manage
their condition is very important," said Sylvie Lauzon, president and chief executive
officer, Diabète Québec. "By empowering people with diabetes with
this tool, it can enhance their ability to manage their condition
and improve their quality of life."
To learn more about RAMQ's coverage of the FreeStyle Libre 2
system, visit here (refer to page 102).
To learn more about the FreeStyle Libre 2 flash glucose
monitoring system, visit www.MyFreeStyle.ca.
About Abbott:
Abbott is a global healthcare leader that helps people live more
fully at all stages of life. Our portfolio of life-changing
technologies spans the spectrum of healthcare, with leading
businesses and products in diagnostics, medical devices,
nutritionals and branded generic medicines. Our 114,000 colleagues
serve people in more than 160 countries.
Connect with us at www.abbott.com and
on LinkedIn, Facebook, Instagram, X and YouTube.
ADC-96030 v1.0
DISCLAIMERS
* The FreeStyle Libre 2 flash
glucose monitoring system is indicated for measuring interstitial
fluid glucose levels in people aged 4 years and older with diabetes
mellitus. Always read and follow the label/insert.
§ The FreeStyle Libre 2 app is only compatible with
certain mobile devices and operating systems. Please check our
website for more information about device compatibility before
using the app. Use of the FreeStyle Libre 2 app may require
registration with LibreView.
1. Data on File, Abbott Diabetes Care, Inc.
2. Based on a comparison of the currently available list price
of the FreeStyle Libre 2 Glucose Monitoring System versus
competitors' CGM systems. The actual cost to patients may vary
depending on the individual patient's plan design coverage, if any.
Data on File, Abbott Diabetes Care, Inc.
3. Based on the FreeStyle Libre 2 User Manual.
SOURCE Abbott